BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting additional results from a preclinical in vivo proof-of-concept study. The study evaluated BVXV’s innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy; results indicate that the presence of the SARS-COV-2 virus in the lungs of hamsters treated with BiondVax’s NanoAb was “virtually eliminated” and significantly less than the amount of virus detected in the placebo group. Specifically, hamsters infected with SARS-COV-2 that were treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies had more than 30 times lower lung viral titer on average compared to those treated with inhaled placebo. This information follow data indicating that NanoAb treatment resulted in significantly milder illness and faster recovery in comparison to the placebo group.
According to the announcement, BiondVax is formulating its NanoAbs as a self‑administered inhaled drug for treatment and potential prophylactic prevention of COVID-19, with the first in-human phase 1/2a clinical trial slated for this year. “We are thrilled with the results of this ongoing trial,” said BiondVax CEO Amir Reichman in the press release. “This study is not only a proof-of-concept for the inhaled COVID-19 NanoAb, but also lights the way to development of a larger NanoAb pipeline. The current omicron outbreak in China has demonstrated that continuous development of innovative and safe therapeutics for COVID-19 is the more effective and economical way to contain this disease. Having a self-administered inhaled therapeutic for those already infected that may also be used as prophylactic prevention for those at risk will address current unmet needs, potentially bring massive relief to global public health, and save millions of lives going forward. I’m proud of the BiondVax team who are scaling-up in-house manufacturing of the NanoAbs and are already beginning to prepare for the next NanoAbs as therapies for other underserved medical conditions such as psoriasis and asthma.”
To view the full press release, visit https://ibn.fm/dIPZ6
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals, a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its prior vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nonosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork.